158 related articles for article (PubMed ID: 30925541)
21. Killing two birds with one stone: response to pembrolizumab in a patient with metastatic melanoma and B-cell chronic lymphocytic leukaemia.
Arenbergerova M; Fialova A; Arenberger P; Gkalpakiotis S; Jirasek T; Srp A; Novotna A; Frankova H
J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):e72-e74. PubMed ID: 28833722
[No Abstract] [Full Text] [Related]
22. Combined anti-inflammatory and low-dose antiproliferative therapy for squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
Reimer A; Lu S; He Y; Bruckner-Tuderman L; Technau-Hafsi K; Meiss F; Has C; von Bubnoff D
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):e1-e3. PubMed ID: 31374134
[No Abstract] [Full Text] [Related]
23. A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder.
Kao C; McNamara M; Alley C; Spector N; Jauhari S; Gupta RT; Zhang T; Zhu J
Clin Genitourin Cancer; 2019 Jun; 17(3):e672-e677. PubMed ID: 31097390
[No Abstract] [Full Text] [Related]
24. Advanced melanoma in adults: Pembrolizumab as a treatment option.
Silvinato A; Bernardo WM; Floriano I
Rev Assoc Med Bras (1992); 2020 May; 66(2):100-107. PubMed ID: 32428140
[TBL] [Abstract][Full Text] [Related]
25. Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma.
Vaccaro M; Bertino L; Santarpia M; Altavilla G; Cannavò SP
Dermatol Ther; 2020 Nov; 33(6):e14417. PubMed ID: 33068047
[No Abstract] [Full Text] [Related]
26. Novel treatment of locally advanced cutaneous squamous cell carcinoma with cemiplimab: a case report.
Nelson R; Luu L; Silberstein P; Velagapudi M; Huerter C
Int J Dermatol; 2021 Feb; 60(2):233-235. PubMed ID: 32955136
[No Abstract] [Full Text] [Related]
27. Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study.
Chang ALS; Tran DC; Cannon JGD; Li S; Jeng M; Patel R; Van der Bokke L; Pague A; Brotherton R; Rieger KE; Satpathy AT; Yost KE; Reddy S; Sarin K; Colevas AD
J Am Acad Dermatol; 2019 Feb; 80(2):564-566. PubMed ID: 30145186
[No Abstract] [Full Text] [Related]
28. Cemiplimab removed from reimbursable drugs in France.
Pham F; Reynaud B; Favier B; Darnis S; Amini-Adle M
Eur J Cancer; 2021 May; 149():11-13. PubMed ID: 33812142
[No Abstract] [Full Text] [Related]
29. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma.
Sanchez A; Montaudie H; Bory P; Belgodere X; Passeron T; Lacour JP; Picard A
JAMA Dermatol; 2018 Nov; 154(11):1354-1356. PubMed ID: 30326507
[No Abstract] [Full Text] [Related]
30. Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab.
Di Prima A; Botticelli A; Scalzulli E; Colafigli G; Pepe S; Lisi C; Marchetti P; Martelli M; Foà R; Breccia M
Ann Hematol; 2021 Aug; 100(8):2117-2119. PubMed ID: 32856142
[No Abstract] [Full Text] [Related]
31. Combination regimens and immunologic mechanisms to enhance the efficacy of cemiplimab for cutaneous squamous cell carcinoma.
Hanania HL; Lewis DJ
Expert Rev Anticancer Ther; 2022 Feb; 22(2):237-238. PubMed ID: 34918605
[No Abstract] [Full Text] [Related]
32. A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor.
Chang AL; Kim J; Luciano R; Sullivan-Chang L; Colevas AD
JAMA Dermatol; 2016 Jan; 152(1):106-8. PubMed ID: 26422398
[No Abstract] [Full Text] [Related]
33. Pathological complete response after neoadjuvant pembrolizumab and radiation.
Mynard JN; Conry RM; De Los Santos J; Gordetsky JB; Contreras CM
Clin Exp Dermatol; 2019 Jul; 44(5):570-573. PubMed ID: 30402885
[No Abstract] [Full Text] [Related]
34. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
[No Abstract] [Full Text] [Related]
35. Resistance to PD-1 blockade in melanoma.
Burki TK
Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
[No Abstract] [Full Text] [Related]
36. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
37. [Treating metastatic melanoma: Risk management].
Lebbe C; Robert C
Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
[No Abstract] [Full Text] [Related]
38. Palliative intralesional tumescent methotrexate for recurrent locally advanced periocular cutaneous squamous cell carcinoma.
Carriere C; Baier S; Campana LG; Puviani M; Eisendle K
J Dtsch Dermatol Ges; 2020 Sep; 18(9):1063-1066. PubMed ID: 32909317
[No Abstract] [Full Text] [Related]
39. Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum.
Ameri AH; Mooradian MJ; Emerick KS; Park JC; Wirth LJ; Asgari MM; Tsao H; Lawrence D; Sullivan RJ; Demehri S
Br J Dermatol; 2019 Nov; 181(5):1095-1097. PubMed ID: 31102460
[No Abstract] [Full Text] [Related]
40. Digital ischemia triggered by coronavirus disease 2019 in a patient under cemiplimab treatment.
Serra-García L; Bosch-Amate X; Alamon-Reig F; Giavedoni P; Fuertes I; Morgado-Carrasco D; Iglesias P; Puig S; Mascaró JM
Int J Dermatol; 2021 Jan; 60(1):e30-e32. PubMed ID: 33040324
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
